Osteoporosis in men: underappreciated and undertreated

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–795.

2. Bliuc D, Nguyen ND, Milch VE et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301: 513–521.

3. Hernlund E, Svedbom A, Ivergård M et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8(1): 136.

4. Hopkins RB, Pullenayegum E, Goeree R et al. Estimation of the lifetime risk of hip fracture for women and men in Canada.Osteoporos Int. 2012; 23(3): 921–927.

5. Kaufman JM. Management of osteoporosis in older men. Aging Clin Exp Res. 2021; 33(6): 1439–1452.

6. Haentjens P, Magaziner J, Colón-Emeric CS et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010; 152: 380–390.

7. Binkley N, Adler R, Bilezikian JP. Osteoporosis diagnosis in men: the T-score controversy revisited. Curr Osteoporos Rep. 2014; 12(4): 403–409.

8. Riggs BL, Melton III LJ, Robb RA et al. A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res. 2004; 19: 1945–1954.

9. Seeman E, Bianchi G, Khosla S et al. Bone fragility in men – where are we? Osteoporos Int. 2006; 17: 1577–1583.

10. Ostertag A, Collet C, Chappard C et al. A case–control study of fractures in men with Idiopathic osteoporosis: fractures are associated with older age and low cortical bone density. Bone. 2013; 52: 48–55.

11. Van Pottelbergh I, Goemaere S, Zmierczak H et al. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three generation family study. J Bone Miner Res. 2003; 18: 303–311.

12. van Meurs JB, Trikalinos TA, Ralston SH et al. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008; 299: 1277–1290.

13. Mohamad NV, Soelaiman IN, Chin KY. A concise review of testosterone and bone health. Clin Interv Aging. 2016; 11: 1317–1324.

14. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23(11): 576–581.

15. Mellstrom D, Vandenput L, Mallmim H et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res. 2008; 23: 1552–1560.

16. Finkelstein JS, Lee H, Leder B et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016; 126(3): 1114.

17. Verschueren S, Gielen E, O‘Neill TW et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int. 2013; 24: 87–98.

18. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002; 87(8): 3656.

19. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. Goodwin JS SO N Engl J Med. 2005; 352(2): 154.

20. Watts NB, Leslie WD, Foldes AJ, Miller PD. 2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom. 2013; 16(4): 472–481.

21. Kanis JA, Oden A, Johansson H et al. FRAX((R)) and its applications to clinical practice. Bone. 2009; 44: 734–743.

22. Stepan JJ, Vaculik J, Pavelka K et al. Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int. 2012; 90(5): 365–372.

23. Dent E, Morley JE, Cruz-Jentoft AJ et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018; 22(10): 1148–1161.

24. Harvey NC, Biver E, Kaufman JM et al. The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int. 2017; 28: 447–462.

25. Rizzoli R. Dairy products, yogurts, and bone health. Am J Clin Nutr 2014; 99(5 Suppl): 1256s–1262s.

26. Rizzoli R, Stevenson JC, Bauer JM et al. ESCEO Task Force. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas. 2014; 79: 122–132.

27. Rizzoli R. Nutritional influence on bone: role of gut microbiota. Aging ClinExp Res. 2019; 31(6): 743–751.

28. Giustina A, Adler RA, Binkley N et al. Consensus statement from 2nd international conference on controversies in vitamin D. Rev Endocr Metab Disord 2020; 21: 89–116.

29. Rochira V, Antonio L & Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 2018; 6: 272–285.

30. Kaufman JM, Reginster JY, Boonen S et al. Treatment of osteoporosis in men. Bone. 2013; 53: 134–144.

31. Sawka AM, Papaioannou A, Adachi JD et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005; 6: 39.

32. Boonen S, Lorenc RS, Wenderoth D et al. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open- -label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone. 2012; 51: 383–388.

33. Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009; 29: 311–315.

34. Sato Y, Iwamoto J, Kanoko T et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Int Med. 2005; 165: 743–1748.

35. Lyles KW, Colón-Emeric CS, Magaziner JS, HORIZON Recurrent Fracture Trial, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799–1809.

36. Boonen S, Orwoll E, Magaziner J, HORIZON Recurrent Fracture Trial, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc. 2011; 59: 2084–2090.

37. Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367: 1714–1723.

38. Khan AA, Morrison A, Kendler DL et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017; 20(1): 8–24.

39. Genant HK, Libanati C, Engelke K et al. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone. 2013; 56: 482–488.

40. Smith MR, Egerdie B, Hernández Toriz N. Denosumab HALT Prostate Cancer Study Group, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361: 745–755.

41. Orwoll E, Teglbjærg CS, Langdahl BL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012; 97: 3161–3169.

42. Langdahl BL, Teglbjærg CS, Ho PR et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015; 100: 1335–1342.

43. Tourdi E, Langdahl B, Cohen-Solal M et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105: 11–17.

44. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide (human parathyroid hormone (1–34)) therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18: 9–17.

45. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: 36-month results of a randomized, double- -blind, controlled trial. Arthritis Rheum. 2009; 60: 3346–3355.

46. Díez-Pérez A, Marin F, Eriksen EF et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone. 2019; 120: 1–8.